Actualités
Blog
02/02/2023
Why do preclinical cancer models still fail in the clinic?
We at Oncodesign Services strive to develop alternative Preclinical Cancer Models to better suit your drug development. Read more about our solutions here.
Actualités
19/01/2023
Oncodesign S.A. is now Oncodesign Services S.A.
Oncodesign Services is chane announced the change of name to Oncodesign Services and a new COMEX for 2023.
Actualités
14/12/2022
Oncodesign Services looks to the future
As Oncodesign evolves into Oncodesign Services and begins its journey as an independent business, CEO Fabrice Viviani explains his hopes and plans for the company’s future
Blog
08/11/2022
Why studying the gut microbes could help to cure?
We explore the importance of Gut Microbes on our health by discussing five of those Gut-Organ Axis - brain, intestine, liver, lung, and skin. Read more here.
Communiqué de Presse
19/10/2022
ERES IV acquires a majority stake in Oncodesign Services
ERES IV, advised by Elyan Partners, acquires a majority stake in Oncodesign Services and will file an offer on the company’s remaining shares. Find out more
Communiqué de Presse
30/09/2022
The General Meeting of Oncodesign authorises the allocation of OPM
Each Oncodesign shareholder will receive one OPM share for one ONCODESIGN share held
Communiqué de Presse
28/09/2022
Euronext Paris authorises the listing of OPM shares
Oncodesign Precision Medicine (OPM) and Oncodesign announce that Euronext Paris S.A. has authorised the admission to listing on Euronext Access + market in Paris of OPM’s ordinary shares.
Communiqué de Presse
26/09/2022
Servier exercises the exclusive worldwide license option of their collaboration program LRRK2
Servier and Oncodesign Precision Medicine (OPM) announce that Servier has exercised its exclusive license option for their drug candidate
Communiqué de Presse
22/09/2022
OPM and Servier announce a strategic collaboration to discover new therapeutic targets for pancreatic cancer treatment
Global pharmaceutical group Servier and Oncodesign Precision Medicine (OPM) announce a collaborative research agreement
Communiqué de Presse
01/07/2022
ONCODESIGN announces the separation of its two business lines – Service and Biotech
ONCODESIGN today announced that the Board of Directors has approved the subsidiarisation of its Biotech business.
Actualités
11/04/2022
Parkinson’s Disease: Growing Prevalence And Continued Significant Medical Need
Explore the disease & find out about our strategic R&D collaboration with Servier: info, press releases & video!
Communiqué de Presse
24/02/2022
Abzena, Alira Health and Oncodesign launch DRIVE-Biologics to support access to specialist services
Abzena x Alira Health x Oncodesign: unveil unique integrated solution with specialist services, from biologics discovery to clinical & commercial manufacturing